Preventing infantile spasms from coming back
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests whether a longer course of steroids can keep infantile spasms from returning in babies who have already responded to standard treatment. It may help reduce the chance of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is between 2 and 18 months old.
- Your baby has been diagnosed with infantile spasms and treatment (like prednisolone, ACTH, or vigabatrin) stopped their spasms, confirmed by an EEG.
- Your baby does not have serious high blood pressure, an active infection, or other conditions that would make extended steroid use risky.
- Your baby has not used any artisanal cannabis product in the last 14 days.
- Your baby is not currently on the ketogenic diet.
- Your baby does not have a vagal nerve stimulator that was implanted or adjusted recently, and has not had epilepsy surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a high-dose steroid (prednisolone) to vigabatrin works better than vigabatrin alone for infants with infantile spasms. It may help reduce seizures and improve early development, but your child’s prior treatments and health conditions must fit the study rules.
This study follows children and teens with rare forms of epilepsy to better understand their condition over time in real-life care. It may help doctors improve future care plans and support for families.
This Phase 2 trial studies fenfluramine to treat infantile spasms that haven’t improved after standard medicines (ACTH and vigabatrin). If you/your child has ongoing seizures, the study may offer another treatment option and will monitor safety closely, especially heart-related side effects.
This study compares two types of brain stimulation—deep brain stimulation (DBS) and vagus nerve stimulation (VNS)—to see which is better at reducing epileptic spasms in children and teens who have not responded to at least two seizure medicines. The goal is to find a treatment that can help control seizures when medications have not worked.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
Hear when a new West Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.